You have   6 free profiles   left this month    Start Your Free Trial ➤
Hey, we noticed you're a RelSci Pro subscriber! Would you like to view the page there? View on RelSci Pro ➤

James A. Abrahamson

Chairman & Chief Executive Officer at SkySpectrum LLC
Relationship Science aggregates deep and verified information on over 6 million influential decision makers and the over 1.5 million organizations with which they are associated. From this data, we create a "business social graph" that highlights who knows whom. Here are James A. Abrahamson's strongest connections.

People Most Closely Connected to James A. Abrahamson

Click the names below to expand relationship details.
John P. Nelson
Chairman & Chief Executive Officer at SilverStone Group, Inc.
Howell M. Estes III
President at Howell Estes & Associates, Inc.
Michael P. C. Carns
Senior Fellow at Institute for Defense Analyses
Nicholas S. Cyprus
Former Vice President, Controller & Chief Accounting Officer at General Motors Company
Warren C. Jensen
Chief Financial Officer & President of International at Acxiom Corporation
Martin C. Faga
Former President & Chief Executive Officer at The MITRE Corp.
Lawrence A. Hough
Founder at Stuart Mill Capital, Inc.
Jeffrey R. Tarr
Member, Management Board at Stanford University - Stanford Graduate School of Business
Kimberly Till
Chief Executive Officer & Director at E-Dynamics SA
James Whitehurst
President & Chief Executive Officer at Red Hat, Inc.
James R. Clapper
Director at National Geospatial-Intelligence Agency (NGA)
John P. Stenbit
Former Assistant Secretary of Defense at C3i, Inc.
James M. Simon, Jr.
Chief Strategist, Worldwide Public Sector at Microsoft Corporation
John T. Gerlach
Associate Professor in the Department of Economics & Finance at Sacred Heart University, Inc.
Seymour Jones
Associate Director, Ross Institute of Accounting Research at New York University - Leonard N. Stern School of Business
Carolyn M. Ticknor
Venture Partner at Inflexion Partners
William W. Sprague
Managing Director at Headwaters MB (Private Equity)
Philip S. Schein
Visiting Professor in Cancer Pharmacology at University of Oxford
1,117 more connections are available with a RelSci Professional subscription.